Oragenics closes $16.5M public offering of Series H Preferred Stock and Warrants

ORAGENICS INC

Issued 660,000 shares of Series H Convertible Preferred Stock at $25/unit with warrants to buy 660,000 additional shares.
Preferred Stock converts to common at $2.50 per share; warrants exercise at $25/share for 5 years.
Gross proceeds ~$16.5M; net ~$15M after fees; potential additional $16.5M if all warrants exercised.
Net proceeds to fund ONP-002 concussion trials, repay $3M bridge note, and general corporate purposes.
Preferred Stock carries 9% cumulative dividend payable in common stock; no voting rights except as law requires.

item 1.01 item 3.03 item 5.03 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001641172-25-017575
form_type: 8-K
ticker: OGEN
cik: 0001174940
company_name: ORAGENICS INC
filed_at: 2025-07-02T23:59:59+00:00
discovered_at: 2026-05-14T18:02:43.489198+00:00
generated_at: 2026-05-18T09:35:00.601237+00:00
sec_items: ["1.01", "3.03", "5.03", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001641172-25-017575
json_url: https://secwatch.observer/filing/0001641172-25-017575.json
markdown_url: https://secwatch.observer/filing/0001641172-25-017575.md
text_url: https://secwatch.observer/filing/0001641172-25-017575.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1174940/000164117225017575/0001641172-25-017575-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1174940/000164117225017575/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001641172-25-017575

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.